Emicizumab for Hemophilia: Takeaways from Phase 3 HAVEN Trial Data

Doris Quon, MD, Medical Director at the Orthopaedic Hemophilia Treatment Center, discusses the main takeaways from phase 3 HAVEN trial data for emicizumab (Hemlibra) prophylaxis in hemophilia. 


The phase 3 HAVEN 1 data was for adults and adolescents, and what it showed was that Hemlibra prophylaxis can reduce the annualized bleed rate and compared to no prophylaxis, the reduction in the bleed rate was 87%. And there was the ability to do the intra-patient comparison, so patients were monitored for 6 months prior to going into the HAVEN trial. They logged their bleeds as well as their use of clotting factor bypass agents, and even there there was a reduction in the bleeding episodes, 79% I believe.
So the takeaway shows that there is a reduction in the bleed rate. There were safety signals, but I think that good communication is the key. Talk to the patient prior to starting the drugs and make a plan when they have a bleeding event to either call the health care team or to have a plan for the bleeding event, what to use, what not to use, and how to treat it.

Most Popular

Related Articles

Although the leading treatment for hemophilia is a replacement therapy in the form of both plasma-derived and rF products, research is underway for the discovery of novel agents.
A panel of experts reviews appropriate use of assays and testing in patients with hemophilia to guide treatment in the setting of multidisciplinary management.
Doris V. Quon, MD, helps patient Eric Mamos share the story of his diagnosis of hemophilia at an early age and review the symptoms associated with this disease.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.